Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis

Ami Vyas,1 Meghan Gabriel,2 Sobha Kurian3 1Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, USA; 2Pharmacy Quality Alliance, Alexandria, VA, USA; 3West Virginia University, School of Medicine, Morgantown, WV, USACorrespondence: Ami VyasDepartment of Pha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vyas A, Gabriel M, Kurian S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	guideline-concordant treatment decomposition her2-negative breast cancer seer-medicare database Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3dd7f9389d584259b1f2f2367ba707ce
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3dd7f9389d584259b1f2f2367ba707ce
record_format	dspace
spelling	oai:doaj.org-article:3dd7f9389d584259b1f2f2367ba707ce2021-12-02T14:38:14ZDisparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis1179-1314https://doaj.org/article/3dd7f9389d584259b1f2f2367ba707ce2021-04-01T00:00:00Zhttps://www.dovepress.com/disparities-in-guideline-concordant-initial-systemic-treatment-in-wome-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Ami Vyas,1 Meghan Gabriel,2 Sobha Kurian3 1Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, USA; 2Pharmacy Quality Alliance, Alexandria, VA, USA; 3West Virginia University, School of Medicine, Morgantown, WV, USACorrespondence: Ami VyasDepartment of Pharmacy Practice, College of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Kingston, RI, 02881, USATel +1-401-874-7255Fax +1-401-874-2717Email avyas@uri.eduBackground: Data on guideline-concordant initial systemic treatment among women with HER2-negative metastatic breast cancer (MBC) are limited. We determined the proportion of women with HER2-negative MBC who received guideline-concordant treatment and the extent to which independent variables explained differences in guideline-concordant treatment by hormone receptor (HR) status.Methods: We conducted a retrospective cohort study using the SEER-Medicare database. We included women age > 65 years diagnosed with HER2-negative MBC during 2010– 2013. We used the National Comprehensive Cancer Network treatment guidelines to determine guideline-concordant initial treatment within the first 6 months of a cancer diagnosis. We conducted a multivariable logistic regression to identify the significant predictors of guideline-concordant treatment and a non-linear decomposition method to examine disparities by HR status.Results: Among 1089 eligible women, 72.3% received guideline-concordant treatment. Compared to women who did not receive guideline-concordant treatment, women who received guideline-concordant treatment were more like to be comparatively older (p< 0.05), married (p=0.0171), resided in areas with higher proportion of people age ≥ 25 years with at least four years of college education, and had positive HR status (p< 0.0001). Approximately 8% of the disparity in guideline-concordant treatment by HR status was explained by their observed characteristics. Need-related factors explained the highest proportion (66.9%) of the disparity.Conclusion: Our findings indicate improvement of care for older women, who are single/divorced, have negative HR status, and who live in area with lower education levels. Unexplained disparities in guideline-concordant treatment by HR status can be attributed to patient preferences for treatment, physician-level factors, and perceptions.Keywords: guideline-concordant treatment, decomposition, HER2-negative, breast cancer, SEER-Medicare databaseVyas AGabriel MKurian SDove Medical Pressarticleguideline-concordant treatmentdecompositionher2-negativebreast cancerseer-medicare databaseNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 13, Pp 259-269 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	guideline-concordant treatment decomposition her2-negative breast cancer seer-medicare database Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	guideline-concordant treatment decomposition her2-negative breast cancer seer-medicare database Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Vyas A Gabriel M Kurian S Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis
description	Ami Vyas,1 Meghan Gabriel,2 Sobha Kurian3 1Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, USA; 2Pharmacy Quality Alliance, Alexandria, VA, USA; 3West Virginia University, School of Medicine, Morgantown, WV, USACorrespondence: Ami VyasDepartment of Pharmacy Practice, College of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Kingston, RI, 02881, USATel +1-401-874-7255Fax +1-401-874-2717Email avyas@uri.eduBackground: Data on guideline-concordant initial systemic treatment among women with HER2-negative metastatic breast cancer (MBC) are limited. We determined the proportion of women with HER2-negative MBC who received guideline-concordant treatment and the extent to which independent variables explained differences in guideline-concordant treatment by hormone receptor (HR) status.Methods: We conducted a retrospective cohort study using the SEER-Medicare database. We included women age > 65 years diagnosed with HER2-negative MBC during 2010– 2013. We used the National Comprehensive Cancer Network treatment guidelines to determine guideline-concordant initial treatment within the first 6 months of a cancer diagnosis. We conducted a multivariable logistic regression to identify the significant predictors of guideline-concordant treatment and a non-linear decomposition method to examine disparities by HR status.Results: Among 1089 eligible women, 72.3% received guideline-concordant treatment. Compared to women who did not receive guideline-concordant treatment, women who received guideline-concordant treatment were more like to be comparatively older (p< 0.05), married (p=0.0171), resided in areas with higher proportion of people age ≥ 25 years with at least four years of college education, and had positive HR status (p< 0.0001). Approximately 8% of the disparity in guideline-concordant treatment by HR status was explained by their observed characteristics. Need-related factors explained the highest proportion (66.9%) of the disparity.Conclusion: Our findings indicate improvement of care for older women, who are single/divorced, have negative HR status, and who live in area with lower education levels. Unexplained disparities in guideline-concordant treatment by HR status can be attributed to patient preferences for treatment, physician-level factors, and perceptions.Keywords: guideline-concordant treatment, decomposition, HER2-negative, breast cancer, SEER-Medicare database
format	article
author	Vyas A Gabriel M Kurian S
author_facet	Vyas A Gabriel M Kurian S
author_sort	Vyas A
title	Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis
title_short	Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis
title_full	Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis
title_fullStr	Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis
title_full_unstemmed	Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis
title_sort	disparities in guideline-concordant initial systemic treatment in women with her2-negative metastatic breast cancer: a seer-medicare analysis
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/3dd7f9389d584259b1f2f2367ba707ce
work_keys_str_mv	AT vyasa disparitiesinguidelineconcordantinitialsystemictreatmentinwomenwithher2negativemetastaticbreastcanceraseermedicareanalysis AT gabrielm disparitiesinguidelineconcordantinitialsystemictreatmentinwomenwithher2negativemetastaticbreastcanceraseermedicareanalysis AT kurians disparitiesinguidelineconcordantinitialsystemictreatmentinwomenwithher2negativemetastaticbreastcanceraseermedicareanalysis
_version_	1718390944779206656

Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis

Ejemplares similares